Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma

N6-methyladenosine (m6A) modification can regulate a variety of biological processes. However, the implications of m6A modification in lung adenocarcinoma (LUAD) remain largely unknown. Here, we systematically evaluated the m6A modification features in more than 2400 LUAD samples by analyzing the multi-omics features of 23 m6A regulators. We depicted the genetic variation features of m6A regulators, and found mutations of FTO and YTHDF3 were linked to worse overall survival. Many m6A regulators were aberrantly expressed in tumors, among which FTO, IGF2BP3, YTHDF1 and RBM15 showed consistent alteration features across 11 independent cohorts. Besides, the regulator-pathway interaction network demonstrated that m6A modification was associated with various biological pathways, including immune-related pathways. The correlation between m6A regulators and tumor microenvironment was also assessed. We found that LRPPRC was negatively correlated with most tumor-infiltrating immune cells. On the other hand, we established a scoring tool named m6Sig, which was positively correlated with PD-L1 expression and could reflect both the tumor microenvironment characterization and prognosis of LUAD patients. Comparison of CNV between high and low m6Sig groups revealed differences on chromosome 7. Application of m6Sig on an anti-PD-L1 immunotherapy cohort confirmed that the high m6Sig group demonstrated therapeutic advantages and clinical benefits. Our study indicated that m6A modification is involved in many aspects of LUAD and contributes to tumor microenvironment formation. A better understanding of m6A modification will provide more insights into the molecular mechanisms of LUAD and facilitate developing more effective personalized treatment strategies. A web application was built along with this study (http://www.bioinfo-zs.com/luadexpress/).

[1]  I. Mohr,et al.  RNA m6 A modification enzymes shape innate responses to DNA by regulating interferon β , 2018, Genes & development.

[2]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[3]  D. Matei,et al.  FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling , 2020, Cancer Research.

[4]  S. Ju,et al.  The potential role of RNA N6-methyladenosine in Cancer progression , 2020, Molecular Cancer.

[5]  Hao Yu,et al.  Mechanism of RNA modification N6-methyladenosine in human cancer , 2020, Molecular Cancer.

[6]  Chunlai Lu,et al.  The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization , 2019, Epigenetics & Chromatin.

[7]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[8]  Aviad Tsherniak,et al.  Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines , 2019, bioRxiv.

[9]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[10]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[11]  X. Hua,et al.  Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study , 2016, PLoS medicine.

[12]  H. Ji,et al.  YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression , 2019, Nature Communications.

[13]  R. Gibbs,et al.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. , 2018, Cell reports.

[14]  John E. J. Rasko,et al.  Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[15]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[16]  Yi-di Guan,et al.  Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma , 2019, Front. Oncol..

[17]  Ying Jin,et al.  m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. , 2018, Biochemical and biophysical research communications.

[18]  Deborah S. Barkauskas,et al.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity , 2016, Science.

[19]  Jie Jin,et al.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. , 2017, Cancer cell.

[20]  H. Tian,et al.  Twenty-gene-based prognostic model predicts lung adenocarcinoma survival , 2018, OncoTargets and therapy.

[21]  P. A. Futreal,et al.  Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma , 2020, Nature Communications.

[22]  Ludmila V. Danilova,et al.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[23]  Tian Xie,et al.  The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  Chuan He,et al.  Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells , 2019, Nature.

[25]  Samie R. Jaffrey,et al.  m6A RNA methylation promotes XIST-mediated transcriptional repression , 2016, Nature.

[26]  Masafumi Ito,et al.  Mesenchymal-epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma. , 2019, Japanese journal of clinical oncology.

[27]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[28]  Congcong Yan,et al.  Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer , 2020, Journal for ImmunoTherapy of Cancer.

[29]  Jionglong Su,et al.  WHISTLE: a high-accuracy map of the human N6-methyladenosine (m6A) epitranscriptome predicted using a machine learning approach , 2019, Nucleic acids research.

[30]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[31]  Jing Sun,et al.  Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non–small cell lung cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[32]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[33]  Beverley Balkau,et al.  Variation in FTO contributes to childhood obesity and severe adult obesity , 2007, Nature Genetics.

[34]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[35]  S. Tavazoie,et al.  N6-methyladenosine marks primary microRNAs for processing , 2015, Nature.

[36]  Liping Chen,et al.  Diagnostic, progressive and prognostic performance of m6A methylation RNA regulators in lung adenocarcinoma , 2020, International journal of biological sciences.

[37]  Tonje G. Lien,et al.  An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment , 2019, Nature Communications.

[38]  Yi-long Wu,et al.  Stromal PD‐L1–Positive Regulatory T cells and PD‐1–Positive CD8‐Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD‐1/PD‐L1 Blockade Immunotherapy , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Chao Qin,et al.  The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma , 2017, Oncotarget.

[40]  James Strait,et al.  Genome-Wide Association Scan Shows Genetic Variants in the FTO Gene Are Associated with Obesity-Related Traits , 2007, PLoS genetics.

[41]  Ya-Nan Wang,et al.  RNA N6-Methyladenosine Modifications and the Immune Response , 2020, Journal of immunology research.

[42]  Chengqi Yi,et al.  N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO , 2011, Nature chemical biology.

[43]  Z. Modrušan,et al.  Deconvolution of Blood Microarray Data Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus , 2009, PloS one.

[44]  Chuan He,et al.  RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. , 2020, Cell stem cell.

[45]  Jie Gu,et al.  A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies , 2019, BMC Cancer.

[46]  Yunfei Xu,et al.  The m6A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca2+ influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[47]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[48]  Adam L. Burrack,et al.  Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma , 2019, Cell reports.

[49]  Eivind Hovig,et al.  Profiling networks of distinct immune-cells in tumors , 2016, BMC Bioinformatics.

[50]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[51]  Xue Leng,et al.  Contributions and prognostic values of m6A RNA methylation regulators in non‐small‐cell lung cancer , 2020, Journal of cellular physiology.

[52]  Stefan Hüttelmaier,et al.  Recognition of RNA N6-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation , 2018, Nature Cell Biology.

[53]  Jing Bai,et al.  Molecular characterization and clinical relevance of m6A regulators across 33 cancer types , 2019, Molecular Cancer.

[54]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[55]  N. Cox,et al.  Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.

[56]  Yiming Huang,et al.  FTO Facilitates Lung Adenocarcinoma Cell Progression by Activating Cell Migration Through mRNA Demethylation , 2020, OncoTargets and therapy.

[57]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[58]  G. Ippolito,et al.  Negative Regulation of Mitochondrial Antiviral Signaling Protein–Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection , 2018, Hepatology.

[59]  M. Kupiec,et al.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq , 2012, Nature.

[60]  Mary Goldman,et al.  Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.

[61]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[62]  Yu-Sheng Chen,et al.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism , 2018, Cell Research.

[63]  C. Zhan,et al.  Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies , 2020, Frontiers in Oncology.

[64]  Lijia Ma,et al.  Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation , 2019, Nature Communications.

[65]  Lijie Wen,et al.  Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity , 2020, BMC Urology.

[66]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[67]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[68]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[69]  Noam Stern-Ginossar,et al.  The RNA modification N6-methyladenosine as a novel regulator of the immune system , 2020, Nature Immunology.

[70]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[71]  Y. Liao,et al.  A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancer , 2019, EBioMedicine.

[72]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[73]  C. Zhuang,et al.  N6‐methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO‐PGC‐1α signalling axis , 2019, Journal of cellular and molecular medicine.

[74]  Chunxing Yang,et al.  YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma , 2019, Front. Oncol..

[75]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[76]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[77]  J. Shang,et al.  Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma , 2019, Journal of Translational Medicine.

[78]  Chuan He,et al.  Post-transcriptional gene regulation by mRNA modifications , 2016, Nature Reviews Molecular Cell Biology.

[79]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[80]  Yun-Gui Yang,et al.  N6-methyl-adenosine (m6A) in RNA: An Old Modification with A Novel Epigenetic Function , 2012, Genom. Proteom. Bioinform..

[81]  Nayoung K. D. Kim,et al.  Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma , 2020, Nature Communications.

[82]  C. Martins,et al.  Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells , 2018, Nature Communications.

[83]  Feng Liu,et al.  METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6‐methyladenosine‐dependent primary MicroRNA processing , 2017, Hepatology.

[84]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[85]  Yue Huang,et al.  Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. , 2020, Cancer cell.

[86]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[87]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[88]  Ralph E. Kleiner,et al.  RNA Chemical Proteomics Reveals the N6-Methyladenosine (m6A)-Regulated Protein-RNA Interactome. , 2017, Journal of the American Chemical Society.

[89]  Xiaoyu Chen,et al.  The role of m6A RNA methylation in human cancer , 2019, Molecular Cancer.

[90]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[91]  Sean R. Davis,et al.  GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..

[92]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.